Jacquelyn Sumer
Compliance Officer bei CULLINAN THERAPEUTICS, INC.
Vermögen: 2 Mio $ am 31.03.2024
Profil
Jacquelyn Sumer is currently working as the Secretary, Chief Legal & Compliance Officer at Cullinan Oncology, Inc. She previously worked as the Executive Director & Senior Corporate Counsel at Celgene Corp.
from 2017 to 2018.
She also worked as the Vice President & Assistant General Counsel at Bristol Myers Squibb Co. and as the Chief Legal & Compliance Officer at Genocea Biosciences, Inc. Ms. Sumer completed her undergraduate degree at Bucknell University and her graduate degree at Duke University School of Law.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 22.02.2024 | 94 133 ( 0,22% ) | 2 Mio $ | 31.03.2024 |
Aktive Positionen von Jacquelyn Sumer
| Unternehmen | Position | Beginn |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Compliance Officer | 15.08.2022 |
Ehemalige bekannte Positionen von Jacquelyn Sumer
| Unternehmen | Position | Ende |
|---|---|---|
| CELGENE | Director/Board Member | 01.07.2018 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
| GENOCEA BIOSCIENCES, INC. | Compliance Officer | - |
Ausbildung von Jacquelyn Sumer
| Bucknell University | Undergraduate Degree |
| Duke University School of Law | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| CULLINAN THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
